Corpus Intelligence IC Memo — ST. CHARLES SURGICAL HOSPITAL 2026-04-26 15:54 UTC
IC Memo — ST. CHARLES SURGICAL HOSPITAL
Investment Committee Memorandum | LA | 39 beds | Grade D | EBITDA uplift $2.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ST. CHARLES SURGICAL HOSPITAL

CCN 190300 | ORLEANS PARISH, LA | 39 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

ST. CHARLES SURGICAL HOSPITAL is a 39-bed community hospital in ORLEANS PARISH, LA with $30.3M in net patient revenue and a 0.3% operating margin. The hospital serves a payer mix of 12.3% Medicare, 0.0% Medicaid, and 87.7% commercial.

Thesis: Turnaround. Our ML models identify $2.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 0.3% to 7.6% (+736bps).

Net Revenue HCRIS$30.3M
Current EBITDA COMPUTED$82K
Operating Margin COMPUTED0.3%
Occupancy HCRIS12.8%
Revenue / Bed COMPUTED$776K
Net-to-Gross HCRIS17.3%
Distress Probability MLnan%

2. Market Context & Competitive Position

212
LA Hospitals
-3.5%
State Median Margin
125
Comparable Hospitals

LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of 0.3% places it above the state median. Among 125 size-comparable peers (20-78 beds), the median margin is -4.1%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (20-78), prioritizing same-state peers. 125 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ST. CHARLES SURGICAL HOSPITAL (Target)LA39$30.3M0.3%
UNIVERSITY HOSPITAL & CLINICSLA52$158.9M-33.4%
SOUTHERN REGIONAL MEDICAL CORPLA64$97.3M-50.0%
NEW ORLEANS EAST HOSPITALLA60$77.6M-29.7%
OCHSNER BAYOU LLCLA25$76.5M-0.9%
OUR LADY OF THE ANGELS HOSPITALA36$76.2M-4.9%
CENTRAL LOUISIANA SURGICAL HOSLA24$69.1M7.7%
ABBEVILLE GENERAL HOSPITALLA44$68.5M3.4%
ST. CHARLES PARISH HOSPITALLA27$64.0M-5.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$636K+210bp18mo
Cost to Collect4.5%2.5%$605K+200bp12mo
Denial Rate Reduction12.0%6.5%$599K+198bp12mo
A/R Days Reduction5200.0%3800.0%$368K+122bp9mo
Clean Claim Rate88.0%96.0%$19K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$636K
Cost to Collect
$605K
Denial Rate Reduction
$599K
A/R Days Reduction
$368K
Clean Claim Rate
$19K
Total EBITDA Uplift$2.2M
Current EBITDA$82K
+ RCM Uplift+$2.2M
Pro Forma EBITDA$2.3M
Current Margin0.3%
Pro Forma Margin7.6%
WC Released (1x)$1.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$126K$22.8M181.05x182.8%
Base (11x exit)10.0x11.0x$126K$25.1M199.48x188.4%
Bull Case9.0x11.0x$113K$32.5M286.81x210.1%
Bull (12x exit)9.0x12.0x$113K$35.5M313.18x215.6%
Bear Case11.0x10.0x$139K$11.6M83.95x142.6%
Bear (11x exit)11.0x11.0x$139K$12.8M92.67x147.4%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 12.8%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 125 hospitals with 20-78 beds
  • Same-state prioritization (n=126)
  • Comp margins: P25=-21.3% / P50=-4.1% / P75=4.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.